Drugs / CC-90003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02313012 | Jan 2015 → May 2016 | metastatic neoplasm | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-90003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02313012 ↗ |
| Action | Inhibit | “CC-90003, a Selective Extracellular Signal-Regulated Kinase (ERK) Inhibitor” NCT02313012 ↗ |
| Route | Oral | “CC-90003 by mouth (PO)” NCT02313012 ↗ |